Aktis Oncology filed to go public to finance its miniprotein radiopharmaceutical pipeline, including a Lilly‑partnered program. The company, which has raised roughly $346 million in private financing and counts Eli Lilly, Merck and Bristol Myers Squibb among its backers, plans to use proceeds to advance Ac‑AKY‑1189 and a second asset into phase 1b studies. Aktis highlighted its imaging‑guided patient selection strategy and plans to read out early clinical data in coming years. The IPO will test investor appetite for radiopharma amid renewed interest in targeted alpha approaches. Sources: Aktis SEC filing and industry reporting.